Skip to content

Association of Heart Failure Aggravation and Device-based Sensor Parameters

Association of Heart Failure Aggravation and Device-based Sensor Parameters

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07753135
Acronym
Heartlogic
Enrollment
500
Registered
2026-08-07
Start date
2023-02-01
Completion date
2027-10-31
Last updated
2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Heart Failure

Brief summary

This is a prospective, multicenter, observational patient registry designed to evaluate the association between changes in device-based sensor parameters and heart failure (HF) aggravation in patients implanted with Boston Scientific implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds) equipped with HeartLogic™, Sleep Incline, and Apnea Scan functions. The study will prospectively collect remote monitoring and clinical follow-up data to determine whether changes in individual or combined device-based sensor parameters are associated with worsening HF events and to evaluate the clinical utility of remote monitoring for HF management.

Detailed description

Heart failure remains a leading cause of hospitalization and mortality worldwide, and early identification of clinical deterioration is essential for timely intervention. Contemporary cardiac implantable electronic devices (CIEDs) continuously collect physiological information that may provide early indicators of worsening HF. Individual device-derived parameters, including thoracic impedance, heart rate, respiratory rate, physical activity, and heart sounds, have been investigated for HF monitoring; however, the predictive performance of single parameters has been limited by relatively high false-positive rates. HeartLogic™ is a multiparametric algorithm that integrates multiple physiological signals, including heart sounds (S1 and S3), thoracic impedance, respiratory rate, night heart rate, and physical activity, to estimate the risk of impending HF decompensation. Additional device-based diagnostic features, including Sleep Incline and Apnea Scan, may further reflect changes in congestion and respiratory status associated with worsening HF. The combined use of these device-based sensor parameters has the potential to improve risk stratification and facilitate earlier clinical intervention. This prospective, multicenter observational registry will enroll approximately 500 adult patients with HF or cardiomyopathy who have undergone implantation of a commercially approved Boston Scientific ICD or CRT-D equipped with HeartLogic, Sleep Incline, and Apnea Scan functions. Participants will be followed for approximately 15 months using routine in-clinic device evaluations and monthly remote monitoring through the LATITUDE™ system as part of standard clinical care. Clinical events, device-derived physiological parameters, and routine clinical assessments will be prospectively collected. The primary objective is to evaluate the association between changes in device-based sensor parameters and HF worsening events, including HF hospitalization, emergency department visits requiring intensification of HF therapy, or unplanned outpatient visits requiring modification of HF treatment. Secondary objectives include evaluating the association between device-based sensor parameters and recurrent HF hospitalization after discharge, atrial and ventricular arrhythmia events, cardiovascular mortality, stroke or systemic embolism, and assessing the clinical utility and patient satisfaction of remote monitoring using the LATITUDE™ platform.

Interventions

DEVICEICD/CRT-D equipped with HeartLogic, Sleep Incline, and Apnea Scan functions

Commercially approved Boston Scientific implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds) equipped with HeartLogic, Sleep Incline, and Apnea Scan functions. Device-based physiological parameters are collected through routine device interrogation and remote monitoring using the LATITUDE system as part of standard clinical care.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 19 years or older who provide written informed consent (or consent from a legally authorized representative when applicable) * Diagnosed with heart failure or cardiomyopathy Implanted with a commercially approved Boston Scientific implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) equipped with HeartLogic™, Sleep Incline, and Apnea Scan functions * Enrolled in the LATITUDE™ (NXT 5.0 or later) remote monitoring system and willing to participate in scheduled remote monitoring and follow-up

Exclusion criteria

* Planned heart transplantation or implantation of a ventricular assist device (VAD), or history of VAD implantation within the previous 12 months * Life expectancy of less than 1 year * Inability or unwillingness to comply with the study protocol or follow-up requirements

Design outcomes

Primary

MeasureTime frameDescription
Change in Device-Based Sensor Parameters Associated With Heart Failure Worsening EventsFrom enrollment through the 15-month follow-up periodTo evaluate the association between changes in device-based sensor parameters (including HeartLogic index, heart sounds, thoracic impedance, respiratory rate, night heart rate, physical activity, Sleep Incline, and Apnea Scan) and heart failure worsening events, defined as heart failure hospitalization, emergency department visits requiring intensification of heart failure therapy, or unplanned outpatient visits requiring modification of heart failure treatment.

Secondary

MeasureTime frameDescription
Heart Failure Rehospitalization After Index Heart Failure HospitalizationUp to 3 months after dischargeTo evaluate the association between device-based sensor parameters measured within 3 days before hospital discharge and subsequent heart failure rehospitalization within 1 month or 3 months after discharge.
Cardiac Arrhythmia EventsFrom enrollment through the 15-month follow-up periodTo evaluate the association between changes in device-based sensor parameters and cardiac arrhythmia events, including newly detected atrial fibrillation, atrial fibrillation progression, atrial fibrillation burden, ventricular tachycardia, and ventricular fibrillation.
Cardiovascular MortalityFrom enrollment through the 15-month follow-up periodTo evaluate the association between changes in device-based sensor parameters and cardiovascular death.
Stroke or Systemic EmbolismFrom enrollment through the 15-month follow-up periodTo evaluate the association between changes in device-based sensor parameters and stroke, transient ischemic attack, or systemic embolic events.
Clinical Utility of Remote MonitoringAt the end of the 15-month follow-upTo evaluate the clinical utility of the LATITUDE remote monitoring system, including patient satisfaction assessed using the Home Monitoring Acceptance and Satisfaction Questionnaire (HoMASQ).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026